Krystal Biotech
$275.94
60
+$3.28+1.2% Wednesday 20:00
Statistics
Day High
278.06
Day Low
271.3
52W High
291.93
52W Low
123.36
Volume
351,327
Avg. Volume
-
Mkt Cap
8.07B
P/E Ratio
40.15
Dividend Yield
-
Dividend
-
Upcoming
Earnings
4MayExpected
Expected EPS
1.502244
Actual EPS
N/A
Financials
52.64%Profit Margin
Profitable778.26MRevenue
409.66MNet Income
Analyst Ratings
326.25Average Price Target
The highest estimate is 371.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy 89%
Hold 11%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow KRYS. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Abeona Therapeutics
ABEO
Mkt Cap313.77M
Sangamo Therapeutics
SGMO
Mkt Cap108.54M
Biomarin Pharmaceutical
BMRN
Mkt Cap10.51B
Pfizer
PFE
Mkt Cap156.77B
Vertex Pharmaceuticals
VRTX
Mkt Cap112.22B
Novartis
NVS
Mkt Cap293.34B
About
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Show more...
CEO
Mr. Krish S. Krishnan M.B.A., M.S.
Employees
275
Country
United States
ISIN
US5011471027
Listings
0 Comments
Share your thoughts
FAQ
What is Krystal Biotech stock price today?▼
The current price of KRYS is $275.94 USD — it has increased by +1.2% in the past 24 hours. Watch Krystal Biotech stock price performance more closely on the chart.
What is Krystal Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Krystal Biotech stocks are traded under the ticker KRYS.
Is Krystal Biotech stock price growing?▼
KRYS stock has risen by +4.5% compared to the previous week, the month change is a +10.34% rise, over the last year Krystal Biotech has showed a +66.43% increase.
What is Krystal Biotech market cap?▼
Today Krystal Biotech has the market capitalization of 8.07B
When is the next Krystal Biotech earnings date?▼
Krystal Biotech is going to release the next earnings report on May 04, 2026.
What were Krystal Biotech earnings last quarter?▼
KRYS earnings for the last quarter are 1.7 USD per share, whereas the estimation was 1.54 USD resulting in a +10.08% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Krystal Biotech revenue for the last year?▼
Krystal Biotech revenue for the last year amounts to 778.26M USD.
What is Krystal Biotech net income for the last year?▼
KRYS net income for the last year is 409.66M USD.
How many employees does Krystal Biotech have?▼
As of April 23, 2026, the company has 275 employees.
In which sector is Krystal Biotech located?▼
Krystal Biotech operates in the Health & Wellness sector.
When did Krystal Biotech complete a stock split?▼
Krystal Biotech has not had any recent stock splits.
Where is Krystal Biotech headquartered?▼
Krystal Biotech is headquartered in Pittsburgh, United States.